IP Library Granted Patent US 11,318,230
Granted Patent B2
US 11,318,230 · App. 15/211,986 · Granted May 3, 2022

Platelet-derived growth factor compositions and methods of use thereof

Inventor: Samuel E. Lynch (Franklin, TN)
Assignee: BIOMIMETIC THERAPEUTICS, LLC
A61L27/54A61F2/28A61K9/0063A61K38/1858A61L27/025A61L27/12A61L27/227A61L27/24A61L27/40A61L27/425A61L27/56A61L27/58A61F2002/2835A61F2210/0004A61L2300/414A61L2400/06A61L2430/02A61L2430/06A61L2430/10A61L2430/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,318,230
App. No.
15/211,986
Granted
May 3, 2022
Kind
B2
Abstract

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.

Claims (27)

1. A method for preparing an implant material for promoting growth of bone, periodontium, cartilage, or ligament comprising:

mixing a porous calcium phosphate with a solution comprising platelet derived growth factor (PDGF) having a concentration ranging from about 0.1 mg/mL to about 1.0 mg/mL in a buffer to form the implant material, wherein the calcium phosphate comprises interconnected pores, a porosity greater than 40%, and particles having a size ranging from about 100 microns to about 5000 microns, and the implant material does not comprise demineralized freeze-dried bone allograft.

2. The method of claim 1 , wherein the PDGF is adsorbed to or absorbed by the calcium phosphate.

3. The method of claim 1 , wherein the PDGF comprises recombinant PDGF.

4. The method of claim 1 , wherein the PDGF comprises recombinant human PDGF-BB.

5. method of claim 1 , wherein the solution comprises PDGF having a concentration ranging from about 0.25 mg/mL to about 0.5 mg/mL.

6. The method of claim 1 , wherein the solution comprises PDGF at a concentration of about 0.3 mg/mL.

7. The method of claim 1 , wherein the calcium phosphate comprises tricalcium phosphate.

8. The method of claim 1 , wherein the porous calcium phosphate comprises beta-tricalcium phosphate.

9. The method of claim 1 , wherein the calcium phosphate comprises particles having a size ranging from about 100 microns to about 3000 microns.

10. The method of claim 1 , wherein the calcium phosphate comprises particles having a size ranging from about 250 μm to about 2000 μm.

11. The method of claim 1 , wherein the calcium phosphate comprises particles having a size ranging from about 250 microns to about 1000 microns.

12. The method of claim 1 , further comprising allowing the implant material to sit for about 10 minutes prior to implantation.

13. The method of claim 1 , wherein the method comprises placing the calcium phosphate in a sterile dish, adding the solution of PDGF to the calcium phosphate, mixing the calcium phosphate and solution of PDGF to form the implant material, and allowing the implant material to sit for about 10 minutes at room temperature.

14. method of claim 1 , wherein the implant material is resorbable such that at least 80% of the calcium phosphate is resorbed within one year of being implanted.

15. A method for preparing an implant material for promoting growth of bone, periodontium, ligament or cartilage comprising:

mixing collagen and a porous calcium phosphate with a solution comprising platelet derived growth factor (PDGF) having a concentration ranging from about 0.1 mg/mL to about 1.0 mg/mL in a buffer to form the implant material, wherein the calcium phosphate comprises interconnected pores, a porosity greater than 40%, and particles having a size ranging from about 100 microns to about 5000 microns, and the implant material does not comprise demineralized freeze-dried bone allograft.

16. A kit for preparing an implant material for promoting growth of bone, peridontium, ligament or cartilage comprising:

i) a container comprising a solution comprising PDGF at a concentration ranging from about 0.1 mg/mL to about 1.0 mg/mL in a buffer,

ii) a container comprising a porous calcium phosphate, wherein the calcium phosphate comprises interconnected pores, a porosity greater than 40%, and particles having a size ranging from about 100 microns to about 5000 microns, and the implant material does not comprise demineralized freeze-dried bone allograft; and

iii) instructions for combining the solution with the calcium phosphate to produce the implant material.

17. The kit of claim 16 , wherein the calcium phosphate comprises beta-tricalcium phosphate.

18. A kit for preparing an implant material for promoting growth of bone, peridontium, ligament or cartilage comprising:

i) a container comprising a solution comprises PDGF at a concentration ranging from about 0.1 mg/mL to about 1.0 mg/mL in a buffer,

ii) a container comprising a porous calcium phosphate and collagen, wherein the calcium phosphate comprises interconnected pores, a porosity greater than 40%, and particles having a size ranging from about 100 microns to about 5000 microns, and the implant material does not comprise demineralized freeze-dried bone allograft; and

iii) instructions for combining the solution with the calcium phosphate and the collagen to produce the implant material.

19. The kit of claim 18 , wherein the calcium phosphate comprises beta-tricalcium phosphate.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Nov 19, 2020
From: MIDCAP FUNDING IV TRUST
To: WRIGHT MEDICAL GROUP N.V.; WRIGHT MEDICAL GROUP, INC.; BIOMIMETIC THERAPEUTICS CANADA, INC.; BIOMIMETIC THERAPEUTICS, LLC; BIOMIMETIC THERAPEUTICS USA, INC.; INBONE TECHNOLOGIES, INC.; ORTHOHELIX SURGICAL DESIGNS, INC.; ORTHOPRO, L.L.C.; SOLANA SURGICAL, LLC; TORNIER US HOLDINGS, INC.; TORNIER, INC.; TROOPER HOLDINGS INC.; WHITE BOX ORTHOPEDICS, LLC; WRIGHT MEDICAL CAPITAL, INC.; WRIGHT MEDICAL TECHNOLOGY, INC.; WRIGHT MEDICAL GROUP INTELLECTUAL PROPERTY, INC.
Reel/Frame 054480/0001 →
SECURITY INTEREST Recorded Jun 4, 2018
From: WRIGHT MEDICAL GROUP N.V.; WRIGHT MEDICAL GROUP, INC.; BIOMIMETIC THERAPEUTICS CANADA, INC.; BIOMIMETIC THERAPEUTICS, LLC; BIOMIMETIC THERAPEUTICS USA, INC.; INBONE TECHNOLOGIES, INC.; ORTHOHELIX SURGICAL DESIGNS, INC.
To: MIDCAP FUNDING IV TRUST, AS AGENT
Reel/Frame 046291/0001 →
CHANGE OF NAME Recorded Jul 26, 2016
From: BIOMIMETIC THERAPEUTICS, INC.
To: BIOMIMETIC THERAPEUTICS, LLC
Reel/Frame 039259/0597 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 26, 2016
From: LYNCH, SAMUEL E
To: BIOMIMETIC THERAPEUTICS, INC.
Reel/Frame 039259/0613 →
Continuity (4)
Continuation 11778498 · Jul 16, 2007
Division 11159533 · Jun 23, 2005
Continuation In Part 10965319 · Oct 14, 2004
Related Publication 20170014545A1 · Jan 19, 2017